Xenon Pharmaceuticals (XENE)
(Delayed Data from NSDQ)
$40.15 USD
-0.64 (-1.57%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $39.00 -1.15 (-2.86%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Balance Sheet
Fiscal Year End for Xenon Pharmaceuticals Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 638 | 592 | 552 | 177 | 141 |
Receivables | 1 | 1 | 3 | 2 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 7 | 4 | 3 | 3 |
Total Current Assets | 645 | 600 | 559 | 182 | 145 |
Net Property & Equipment | 10 | 7 | 4 | 4 | 2 |
Investments & Advances | 293 | 129 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 1 | 1 | 0 | 1 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 7 | 8 | 0 | 0 | 0 |
Total Assets | 965 | 754 | 572 | 189 | 148 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 26 | 22 | 14 | 11 | 9 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 5 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 4 | 30 |
Total Current Liabilities | 27 | 23 | 14 | 15 | 43 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 1 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 11 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 37 | 33 | 22 | 18 | 56 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 8 | 8 | 8 |
Common Stock (Par) | 1,436 | 1,065 | 783 | 398 | 294 |
Capital Surplus | 157 | 142 | 118 | 45 | 41 |
Retained Earnings | -665 | -483 | -357 | -278 | -250 |
Other Equity | 0 | -3 | -1 | -1 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 928 | 722 | 550 | 171 | 92 |
Total Liabilities & Shareholder's Equity | 965 | 754 | 572 | 189 | 148 |
Total Common Equity | 928 | 722 | 542 | 164 | 84 |
Shares Outstanding | 65.40 | 62.50 | 51.50 | 35.00 | 28.10 |
Book Value Per Share | 14.19 | 11.54 | 10.53 | 4.68 | 3.00 |
Fiscal Year End for Xenon Pharmaceuticals Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 722 | 700 | 638 | 527 | 540 |
Receivables | 1 | 1 | 1 | 1 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 7 | 6 | 4 | 3 |
Total Current Assets | 728 | 707 | 645 | 531 | 545 |
Net Property & Equipment | 10 | 9 | 10 | 10 | 10 |
Investments & Advances | 129 | 186 | 293 | 112 | 113 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 1 | 0 | 1 | 1 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 7 | 7 | 7 | 7 | 8 |
Total Assets | 884 | 919 | 965 | 671 | 685 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 30 | 21 | 26 | 24 | 27 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 31 | 22 | 27 | 25 | 28 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 40 | 31 | 37 | 35 | 38 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 1,440 | 1,439 | 1,436 | 1,122 | 1,083 |
Capital Surplus | 177 | 164 | 157 | 138 | 139 |
Retained Earnings | -771 | -713 | -665 | -620 | -572 |
Other Equity | -2 | -2 | 0 | -3 | -3 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 844 | 888 | 928 | 637 | 646 |
Total Liabilities & Shareholder's Equity | 884 | 919 | 965 | 671 | 685 |
Total Common Equity | 844 | 888 | 928 | 637 | 646 |
Shares Outstanding | 75.40 | 75.40 | 65.40 | 64.10 | 63.50 |
Book Value Per Share | 11.19 | 11.77 | 14.19 | 9.93 | 10.18 |